Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET/CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clini[...]